Independent support for the role of microglia in Alzheimer’s disease
I was very excited to read about research recently published by a group from Stanford regarding the potential role for microglia in Alzheimer’s disease (http://med.stanford.edu/news/all-news/2014/12/blocking-receptor-in-brains-immune-cells-counters-alzheimers.html). While the work by Karin Andreasson and her team focuses on a receptor protein called EP2, the underlying conclusions of her research – that restoring the activity of microglia to clear A-beta and reduce toxic inflammation, both hallmarks of AD – reinforces the work of GliaCure. Our lead compound, GC021109, targets the P2Y6 receptor with the same effect on microglia. Like Dr. Andreasson, we believe that this approach is likely to have fewer adverse side effects than those therapies that target neurons. It’s very encouraging to find that others may be rowing in the same direction as GliaCure, especially as we’ve started testing this approach in humans!